神經調控市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、區域及競爭格局分類，2021-2031年）

全球神經調控市場預計將從 2025 年的 74.1 億美元成長到 2031 年的 104.8 億美元，複合年成長率為 5.95%。

該領域涵蓋旨在透過直接向神經輸送藥物或進行電刺激來改變生物活性並達到治療效果的醫療技術。推動該領域發展的主要因素是全球人口老化和帕金森氏症等慢性疾病的日益增多，這些疾病需要有效的非鴉片類鎮痛策略。根據世界衛生組織（WHO）2024年的數據，全球有超過30億人患有神經系統疾病，使這些疾病成為全球殘疾的主要原因。這凸顯了此類醫療干預措施的巨大潛在患者群體。

然而，市場成長面臨許多障礙，包括設備成本高昂以及專業醫療基礎設施取得方面的不均衡。嚴格的法規環境和有限的報銷選擇往往阻礙病人就醫，這在資源匱乏的發展中地區尤其普遍。這種不均衡在醫護人員中尤為突出，嚴重限制了醫療服務能力。根據世界衛生組織（世衛組織）2024年的統計數據，高所得國家每10萬居民的神經科醫生數量是低收入國家的70倍之多，這極大地限制了醫療服務在服務不足地區的市場滲透。

市場促進因素

新一代神經調控設備的快速技術進步正在改變醫療保健格局，顯著提升治療精準度和病患療效。製造商致力於將感測功能與封閉回路型系統整合，該系統能夠根據即時神經反饋調整刺激，從而克服電池壽命和療效方面的傳統挑戰。近期監管的成就也印證了這個趨勢，進一步凸顯了感測功能的臨床價值。例如，在2024年1月的新聞稿《美敦力公司首款Percept RC DBS系統獲FDA核准》中，美敦力宣布其能夠採集腦波訊號以進行個人化治療的深部腦部刺激系統獲得FDA核准。這些創新使得治療性介入更加精準，減少了手動調整的需要，從而顯著提升了長期運動障礙患者的照護品質。

此外，主要市場參與者不斷增加研發投入是推動市場成長的次要因素，透過策略整合加速商業化進程並擴大產品組合。主要企業正積極收購專業公司，以拓展微創治療方案，並在薦骨神經調控等高成長領域取得競爭優勢。正如2024年1月波士頓科學公司宣布收購Axonics時所揭露，該公司已同意以約37億美元的股票以金額為準收購這家醫療科技公司。這項大規模投資顯示了業界對生物電子醫學長期盈利的信心。此外，美敦力公司在2024年5月宣布，其神經科學產品組合在該會計年度的全球銷售額將達到94億美元，這進一步印證了當前市場的龐大規模和商業性可行性。

市場挑戰

昂貴的醫療設備和嚴格的報銷政策是限制全球神經調控市場發展的主要阻礙因素。由於保險公司將這些治療方法歸類為「研究性」療法，或要求提供大量證據證明其醫療必要性才能獲得核准，製造商難以獲得廣泛的醫療覆蓋範圍。這一經濟障礙極大地限制了目標患者群體，因為沒有全面保險的個人無法承擔植入和後續維護這些系統所帶來的高昂自付費用。

醫療服務提供者的支付標準降低，進一步加劇了經濟負擔，抑制了先進疼痛管理技術的應用。複雜手術報銷額的減少，也阻礙了醫療機構對必要人員和設備的投入。根據美國麻醉醫師協會2024年11月發布的公告，政府最終確定的明年醫療費用修訂方案將使醫生服務的報銷額降低2.83%，這一變化威脅到提供介入性疼痛治療​​的診所的生存。這些財務限制直接阻礙了神經調控解決方案在醫療產業的廣泛應用。

市場趨勢

腦機介面（BCI）技術的發展是一項重大趨勢，它能夠幫助患者恢復言語和運動功能，使該領域從單純的症狀管理轉向功能重建。研發人員正優先開發可植入式系統，該系統能夠解碼神經訊號，使癱瘓患者能夠操作數位設備，從而滿足神經復健領域一項重要的未滿足需求。新型血管內系統的安全性和有效性已在臨床上得到驗證，這為上述進展提供了有力支持。例如，Synchron公司於2024年9月發布的COMMAND研究結果顯示，其永久性BCI植入達到了主要安全性終點，在為期12個月的研究期間，6名患者均未發生與設備相關的嚴重不利事件。這些發現表明生物電子工程技術已顯著成熟，並確立了BCI作為幫助癱瘓患者恢復獨立生活能力的極具前景的領域的地位。

同時，治療應用正顯著擴展至精神健康領域，尤其是在難治性精神疾病方面。在醫療服務提供者對治療強迫症和憂鬱症的有效非藥物療法的需求推動下，經顱磁刺激 (TMS) 等非侵入性技術正迅速走向商業化。這種廣泛應用也體現在專業神經刺激公司強勁的財務表現上。例如，BrainsWay 在 2024 年 11 月發布的「2024 會計年度第三季財報」中顯示，其季度營收為 1,050 萬美元，年增 26%，這主要得益於其深部 TMS 系統需求的激增。這一趨勢表明，該行業已成功實現向高價值精神疾病領域的多元化發展，並減少了對傳統疼痛管理和運動障礙治療收入的依賴。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球神經調控市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（內部神經調節（脊髓刺激、深部腦刺激、迷走神經刺激、薦椎神經刺激、胃電刺激）、外部神經調節（經皮神經電刺激（TENS）、經顱磁刺激（TMS）、呼吸電刺激（RES）））
  • 依應用方式（脊髓刺激、深部腦部刺激、薦椎神經刺激、迷走神經刺激、胃電刺激、經皮神經電刺激、經顱磁刺激、呼吸電刺激）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美神經調控市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲神經調控市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區神經調控市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東與非洲神經調控市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲神經調控市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球神經調控市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Medtronic PLC
• NanoGen Healthcare Pvt. Ltd.
• Boston Scientific Corporation
• Abbott Laboratories Ltd.
• Livanova plc
• Nevro Corporation
• Neurosigma PLC.
• Neuropace, INC.
• Soterix Medical Inc.
• Aleva Neurotherapeutics SA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Neuromodulation Market is projected to expand from USD 7.41 Billion in 2025 to USD 10.48 Billion by 2031, reflecting a CAGR of 5.95%. This sector encompasses medical technologies designed to alter biological activity for therapeutic gain by delivering pharmaceutical agents or electrical stimulation directly to nerves. Growth is largely fueled by an aging global demographic and the increasing incidence of chronic conditions like Parkinson's disease, which necessitates effective non-opioid pain management strategies. Data from the World Health Organization in 2024 revealed that over 3 billion individuals globally suffer from neurological conditions, establishing these ailments as the primary cause of disability worldwide and underscoring the massive potential patient base for these medical interventions.

However, market growth faces substantial hurdles related to the prohibitive costs of devices and unequal access to specialized medical infrastructure. Strict regulatory environments and limited reimbursement options frequently hinder patient access, a widespread issue in resource-constrained developing regions. This inequality is particularly evident in the workforce, severely restricting care delivery capabilities. According to 2024 World Health Organization statistics, high-income nations benefit from up to 70 times more neurological professionals per 100,000 residents compared to low-income countries, a discrepancy that significantly blocks widespread market adoption in underserved areas.

Market Driver

Rapid technological progress in next-generation neuromodulation devices is transforming the therapeutic environment by improving precision and patient results. Manufacturers are focusing on integrating sensing capabilities and closed-loop systems that adapt stimulation based on real-time neural feedback, thereby resolving earlier issues related to battery life and efficacy. This trend is highlighted by recent regulatory achievements that confirm the clinical value of sensing-enabled features; for instance, Medtronic announced in a January 2024 press release titled 'Medtronic First-of-its-Kind Percept RC DBS System Receives FDA Approval' that it secured approval for a deep brain stimulation system capable of capturing brain signals for personalized treatment. Such innovations enable more precise interventions, lessening the need for manual adjustments and greatly enhancing care quality for patients managing long-term movement disorders.

Additionally, increased research and development spending by major market players serves as a secondary driver, accelerating commercialization and portfolio growth through strategic consolidation. Leading corporations are aggressively acquiring specialized companies to expand their minimally invasive options and gain a competitive edge in high-growth areas such as sacral neuromodulation. As reported in the 'Boston Scientific to Acquire Axonics, Inc.' announcement in January 2024, Boston Scientific agreed to purchase the medical technology firm for an equity value of roughly $3.7 billion. This significant investment demonstrates industry confidence in the long-term profitability of bioelectronic medicine, further evidenced by Medtronic's report in May 2024 that its Neuroscience Portfolio achieved $9.4 billion in global revenue for the fiscal year, showcasing the immense scale and commercial viability of the current market.

Market Challenge

The combination of high device costs and restrictive reimbursement policies represents a major constraint on the global neuromodulation market. Manufacturers struggle to obtain broad insurance coverage because payers frequently label these therapies as investigational or demand extensive proof of medical necessity prior to authorization. This financial obstacle severely restricts the addressable patient population, as individuals lacking comprehensive insurance cannot sustain the significant out-of-pocket costs associated with the implantation and ongoing maintenance of these systems.

This economic strain is exacerbated by cuts in payment rates for healthcare providers, which discourage the utilization of advanced pain management methods. When reimbursement for performing complex procedures declines, medical facilities are less inclined to invest in essential personnel or equipment. According to the American Society of Anesthesiologists in November 2024, the government's finalized fee schedule for the upcoming year introduced a 2.83 percent reduction in reimbursement for physician services, a change that jeopardizes the financial viability of practices providing interventional pain therapies. Such fiscal constraints directly impede the scalability of neuromodulation solutions within the healthcare industry.

Market Trends

The evolution of Brain-Computer Interface (BCI) technologies for speech and motor restoration marks a crucial trend, shifting the sector from simple symptom management to functional recovery. Developers are prioritizing implantable systems that decode neural signals to allow paralyzed patients to operate digital devices, addressing critical unmet needs in neurorehabilitation. This advancement is supported by successful clinical outcomes regarding the safety and efficacy of new endovascular systems; specifically, Synchron announced in its 'COMMAND Study Results' in September 2024 that its permanent BCI implant achieved its primary safety endpoint with no serious device-related adverse events across six patients during a 12-month study. These findings indicate a significant maturation in bioelectronic engineering, establishing BCI as a promising future sector for restoring independence to those with paralysis.

Simultaneously, the market is undergoing significant broadening of therapeutic applications into mental health, especially for treatment-resistant psychiatric disorders. Non-invasive techniques like Transcranial Magnetic Stimulation (TMS) are seeing rapid commercial uptake as providers look for effective, non-pharmaceutical options for obsessive-compulsive disorder and depression. This increasing adoption is mirrored in the strong financial performance of specialized neurostimulation firms; for example, BrainsWay reported in its 'Third Quarter 2024 Financial Results' in November 2024 that quarterly revenue rose 26 percent year-over-year to $10.5 million, fueled largely by surging demand for its Deep TMS systems. This trend underscores the industry's successful diversification into high-value psychiatric segments, lessening its dependence on revenue from traditional pain management and movement disorders.

Key Market Players

• Medtronic PLC
• NanoGen Healthcare Pvt. Ltd.
• Boston Scientific Corporation
• Abbott Laboratories Ltd.
• Livanova plc
• Nevro Corporation
• Neurosigma PLC.
• Neuropace, INC.
• Soterix Medical Inc.
• Aleva Neurotherapeutics SA

Report Scope

In this report, the Global Neuromodulation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuromodulation Market, By Type

• Internal Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation)
• External Neuromodulation(Transcutaneous Electrical Nerve Stimulation (TENS), Transcranial Magnetic Stimulation (TMS), Respiratory Electrical Stimulation (RES))

Neuromodulation Market, By Application

• Spinal Cord Stimulation
• Deep Brain Stimulation
• Sacral Nerve Stimulation
• Vagus Nerve Stimulation
• Gastric Electrical Stimulation
• Transcutaneous Electrical Nerve Stimulation
• Transcranial Magnetic Stimulation
• Respiratory Electrical Stimulation

Neuromodulation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neuromodulation Market.

Available Customizations:

Global Neuromodulation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neuromodulation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Internal Neuromodulation (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation), External Neuromodulation(Transcutaneous Electrical Nerve Stimulation (TENS), Transcranial Magnetic Stimulation (TMS), Respiratory Electrical Stimulation (RES)))
  • 5.2.2. By Application (Spinal Cord Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Gastric Electrical Stimulation, Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation, Respiratory Electrical Stimulation)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Neuromodulation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neuromodulation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Neuromodulation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Neuromodulation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Neuromodulation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neuromodulation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Neuromodulation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Neuromodulation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Neuromodulation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Neuromodulation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Neuromodulation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Neuromodulation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Neuromodulation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Neuromodulation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Neuromodulation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Neuromodulation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Neuromodulation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Neuromodulation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Neuromodulation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Neuromodulation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Neuromodulation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Neuromodulation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Neuromodulation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Neuromodulation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Neuromodulation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Medtronic PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. NanoGen Healthcare Pvt. Ltd.
• 15.3. Boston Scientific Corporation
• 15.4. Abbott Laboratories Ltd.
• 15.5. Livanova plc
• 15.6. Nevro Corporation
• 15.7. Neurosigma PLC.
• 15.8. Neuropace, INC.
• 15.9. Soterix Medical Inc.
• 15.10. Aleva Neurotherapeutics SA

16. Strategic Recommendations

17. About Us & Disclaimer